Keywords
oncology drugs
pharmaceutical market
drug provision
marketing analysis
pharmacoeconomic assessment
pharmaceutical market
drug provision
marketing analysis
pharmacoeconomic assessment
Abstract
Oncological diseases remain one of the key medical and social problems in the Republic of Kazakhstan, forming a significant burden on the health care system and the mechanism of drug provision. The purpose of the study was a comprehensive assessment of the current state of the pharmaceutical market of antitumor drugs of the Republic of Kazakhstan in the context of the implementation of the Comprehensive Plan for 2023-2027 with an emphasis on the regulatory environment, assortment structure, sources of supply of these drugs and pharmacoeconomic characteristics of therapy. This study utilized structural, comparative marketing and pharmacoeconomic analysis methods, using data from the State Register of Medicines, official statistics from the Ministry of Health of the Republic of Kazakhstan, and information on actual procurement volumes of oncology drugs in 2025 (as of October). An analysis of the product range by Anatomical Therapeutic Chemical (ATC) classification, dosage forms, and trade names was conducted, the role of orphan drugs was assessed, and procurement leaders were identified. The average cost per package and per treatment course for key anticancer drugs was calculated based on instructions for medical use and standard clinical treatment regimens. The study results showed that the pharmaceutical market for oncology drugs in Kazakhstan is characterized by a high concentration of costs on a limited list of targeted and biological drugs, while imports predominate. A significant pharmacoeconomic differentiation was identified between classic cytostatics and innovative drugs, which is of significant importance for planning public funding and optimizing drug provision for cancer patients.
References
1. Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., et al. (2017). Global surveillance of trends in cancer survival 2000–14 (CONCORD‑3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers in 322 population‑based registries in 71 countries. The Lancet, 391(10125), 1023–1075. DOI: https://doi.org/10.1016/S0140-6736(17)33326-3
2. Ashadul Sk M., Hemalatha K., Matada G.S.P., Pal R., Manjushree B.V., Mounika S., Haripriya E., Viji M.P., Anjan D. (2025). Current developments in PI3K-based anticancer agents: Designing strategies, biological activity, selectivity, structure-activity correlation, and docking insight. Bioorganic Chemistry, 154, 108011. DOI: https://doi.org/10.1016/j.bioorg.2024.108011.
3. Beylerli, O., Gareev, I., Musaev, E. et al. (2025). New approaches to targeted drug therapy of intracranial tumors. Cell Death Discov. 11, 111. DOI: https://doi.org/10.1038/s41420-025-02358-3
4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68(6), 394-424. DOI: https://doi.org/10.3322/caac.21492
5. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022 (2024). GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 74(3), 229-263. DOI: https://doi.org/10.3322/caac.21834
6. Farmer, P., Frenk, J., Knaul, F. M., et al. (2010). Expansion of cancer care and control in countries of low and middle income: a call to action. The Lancet, 376(9747), 1186–1193. DOI: https://doi.org/10.1016/S0140-6736(10)61152-X
7. Gopienko I.A., Zyryanov S.K. (2024). Marketing analysis of the Russian pharmaceutical market of oxaliplatin. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice, (1), 72-77. (In Russ.) DOI: https://doi.org/10.37489/2588-0519-2024-1-72-77
8. Hanna, T. P., King, W. D., Thibodeau, S., Jalink, M., Paulin, G. A., Harvey Jones, E., … & Sullivan, R. (2020). Mortality due to cancer treatment delay: systematic review and meta analysis. BMJ, 371, m4087. DOI: https://doi.org/10.1136/bmj.m4087
9. Hudson, T. J., Anderson, W., Artez, A., et al. (2010). International network of cancer genome projects. Nature, 464(7291), 993–998. DOI: https://doi.org/10.1038/nature08987
10. Khorsandia D., Farahanib A., Zarepourcd A., Khosravief A., Iravani S. and Zarrabi A. (2025). Bridging technology and medicine: artificial intelligence in targeted anticancer drug delivery. RSC Adv., 15, 27795-27815. DOI: https://doi.org/10.1039/D5RA03747F
11. Ley, T. J., Miller, C., Ding, L., et al. (2008). DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature, 456(7218), 66–72. DOI: https://doi.org/10.1038/nature07485
12. Melnikov A. M. Melnikova O.A. (2021). The market of drugs for the treatment of skin cancer. VI International (76th All-Russian) Scientific and Practical Conference "Current Issues of Modern Medical Science and Healthcare", 1054-1058, URL: http://elib.usma.ru
13. «On approval of maximum manufacturer prices for the trade name of a medicine, maximum prices for the trade name of a medicine for retail and wholesale sales» Order of the acting Minister of Health of the Republic of Kazakhstan dated August 27, 2021, No. ҚР ДСМ-9 (as amended and supplemented on July 18, 2025). URL: https://adilet.zan.kz/rus/docs/V2100024229 (accessed: December 4, 2025)
14. «On approval of maximum prices for the trade name of medicines and medical devices within the framework of the guaranteed volume of free medical care and (or) in the compulsory social health insurance system» Order of the Minister of Health of the Republic of Kazakhstan dated August 5, 2021 No. ҚР ДСМ-77 (as amended and supplemented on 03.12.2025). URL: https://adilet.zan.kz/rus/docs/V2100023886 (date accessed: 04.12.2025)
15. «On approval of the Comprehensive Plan to Combat Cancer in the Republic of Kazakhstan for 2023-2027» Resolution of the Government of the Republic of Kazakhstan dated October 5, 2023 No. 874. URL: https://adilet.zan.kz/rus/docs/P2300000874 (accessed: 04.12.2025)
16. «On approval of the list of diseases for which specialized medical care in inpatient settings is provided on a planned basis» Order of the Minister of Health of the Republic of Kazakhstan dated December 11, 2020 No. ҚР ДСМ-258/2020. (as amended and supplemented on November 22, 2021). URL: https://adilet.zan.kz/rus/docs/V2000021784 (date accessed: 04.12.2025)
17. «On approval of the list of orphan diseases and drugs for their treatment (orphan)» Order of the Minister of Health of the Republic of Kazakhstan dated October 20, 2020 No. KR DSM - 142/2020. (as amended and supplemented on 04.12.2025). URL: https://adilet.zan.kz/rus/docs/V2000021479#z65 (accessed: December 4, 2025)
18. «On Approval of the Standard for the Organization of Oncology Care for the Population of the Republic of Kazakhstan» Order of the Minister of Health of the Republic of Kazakhstan dated November 12, 2021 No. KR DSM-112. (as amended on October 1, 2025). URL: https://adilet.zan.kz/rus/docs/V2100025167 (accessed: 04.12.2025)
19. «On Public Health and the Healthcare System» Code of the Republic of Kazakhstan dated July 7, 2020 No. 360-VI ZRK (as amended on December 4, 2025). URL: https://adilet.zan.kz/eng/docs/K2000000360 (accessed on December 4, 2025)
20. Petrukhina I.K., Ryazanova T.K., Gladunova E.P., Lazarev A.M., Krivova A.A. (2023). Sales of antitumor drugs in the retail segment of the Russian pharmaceutical market. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology, 16(4), 619-629. DOI: https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.212
21. Rikhsiyeva O.G., Rajabova N.Kh. (2025). Methodological approaches to conducting marketing research of the anticancer drug market in Uzbekistan. Eurasian journal of medical and natural sciences, 5(7), 125-131. DOI: https://doi.org/10.5281/zenodo.16604213
22. Robert, C., Schachter, J., Long, G. V., et al. (2015). Pembrolizumab versus ipilimumab in advanced melanoma. New England Journal of Medicine, 372(26), 2521–2532. DOI: https://doi.org/10.1056/NEJMoa1503093
23. State Register of Medicines and Medical Devices (2025). National Center for Expertise of Medicines and Medical Devices of the Ministry of Health of the Republic of Kazakhstan. URL: https://register.ndda.kz/#/reestr (accessed: December 4, 2025)
24. Statistical collection: Health of the population of the Republic of Kazakhstan and activities of healthcare organizations in 2024 (2025). National Scientific Center for Healthcare Development named after Salidat Kairbekova MH RK. 399 p.
25. Sullivan, R., Alatise, O. I., Anderson, B. O., et al. (2019). Global cancer surgery: delivering safe, affordable, and timely cancer surgery. The Lancet Oncology, 16(11), 1193–1224. DOI: https://doi.org/10.1016/S1470-2045(15)00223-5
26. Topalian, S. L., Hodi, F. S., Brahmer, J. R., et al. (2012). Safety, activity, and immune correlates of anti–PD‑1 antibody in cancer. New England Journal of Medicine, 366(26), 2443–2454. DOI: https://doi.org/10.1056/NEJMoa1200690
27. Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM, Cancer Genome Atlas Research Network (2013). The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet., 45(10), 1113-1120. DOI: https://doi.org/10.1038/ng.2764
28. Wild, C. P., Weiderpass, E., & Stewart, B. W. (2020). World Cancer Report: Cancer research for cancer prevention. International Agency for Research on Cancer, IARC. Press, PMID: 39432694. URL: https://pubmed.ncbi.nlm.nih.gov/39432694/
29. Wu D., Yang K., He R., Yin R. and Shui L. (2025). Antibody-drug conjugates in cancer therapy: current advances and prospects for breakthroughs. Front. Cell Dev. Biol. 13:1669592. DOI: https://doi.org/10.3389/fcell.2025.1669592
30. Zhetesbayeva Sh.K., Tulebayev Ye.A. (2025). Marketing analysis of the oncological drugs market in Kazakhstan: barriers, trends and development ways. CAIMU Bulletin SIJ. 1(10), 145-149. URL: www.nimsi.kg
